Dimerix Limited (AU:DXB) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Dimerix Limited has announced the successful completion of a fifth scheduled review by the Independent Data Monitoring Committee (IDMC) for its Phase 3 ACTION3 kidney trial, with no safety concerns reported. The trial will continue as planned, reinforcing the strong safety profile of their DMX-200 treatment for FSGS kidney disease. This development brings hope to patients with limited treatment options.
For further insights into AU:DXB stock, check out TipRanks’ Stock Analysis page.